{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:15:23Z","timestamp":1792815323429,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T00:00:00Z","timestamp":1729814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["G040319N"],"award-info":[{"award-number":["G040319N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1S30319N"],"award-info":[{"award-number":["1S30319N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1275023N"],"award-info":[{"award-number":["1275023N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1S40923N"],"award-info":[{"award-number":["1S40923N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["1S73120N"],"award-info":[{"award-number":["1S73120N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Research Foundation Flanders","doi-asserted-by":"publisher","award":["GOE8920N"],"award-info":[{"award-number":["GOE8920N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007229","name":"Bijzonder Onderzoeksfonds UGent","doi-asserted-by":"publisher","award":["BOF21\/GOA\/033"],"award-info":[{"award-number":["BOF21\/GOA\/033"]}],"id":[{"id":"10.13039\/501100007229","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtn.2024.102372","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T03:19:11Z","timestamp":1730258351000},"page":"102372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of mRNA-galsomes and LNPs in enhancing HIV-specific T\u00a0cell responses across various lymphoid organs"],"prefix":"10.1016","volume":"35","author":[{"given":"Sigrid","family":"D\u2019haese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"den Roover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rein","family":"Verbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilke","family":"Aernout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"Meulewater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Cosyns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessy","family":"Meert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Vanbellingen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thessa","family":"Laeremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ine","family":"Lentacker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-3696","authenticated-orcid":false,"given":"Joeri L.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102372_bib1","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body\u00a0AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib2","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The End of AIDS: HIV Infection as a Chronic Disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2024.102372_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/imr.12079","article-title":"HIV-associated chronic immune activation","volume":"254","author":"Paiardini","year":"2013","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.omtn.2024.102372_bib4","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/nm.4411","article-title":"Defining total-body AIDS-virus burden with implications for curative strategies","volume":"23","author":"Estes","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib5","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clim.2011.10.010","article-title":"A phase I\/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption","volume":"142","author":"Allard","year":"2012","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib6","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1097\/QAD.0000000000002026","article-title":"Phase I clinical trial of an intranodally administered mRNA-based therapeutic vaccine against HIV-1 infection","volume":"32","author":"Leal","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.omtn.2024.102372_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2013.00086","article-title":"Cell-mediated immunity in elite controllers naturally controlling hiv viral load","volume":"4","author":"Genovese","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib8","doi-asserted-by":"crossref","DOI":"10.4172\/2155-6113.1000139","article-title":"Elite controllers and long-term nonprogressors: Models for HIV vaccine development? at OMICS International","volume":"3","author":"Okulicz","year":"2012","journal-title":"J. Aids Clin. Res."},{"key":"10.1016\/j.omtn.2024.102372_bib9","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy","volume":"27","author":"Deeks","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2024.102372_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000917","article-title":"Perforin Expression Directly Ex\u00a0Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control","volume":"6","author":"Hersperger","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.omtn.2024.102372_bib11","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1182\/blood-2005-12-4818","article-title":"HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T\u00a0cells","volume":"107","author":"Betts","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102372_bib12","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/ni845","article-title":"HIV-specific CD8+ T\u00a0cell proliferation is coupled to perforin expression and is maintained in nonprogressors","volume":"3","author":"Migueles","year":"2002","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib13","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.immuni.2008.10.010","article-title":"Article Lytic Granule Loading of CD8\u00a0+ T Cells Is Required for HIV-Infected Cell Elimination Associated with Immune Control","volume":"29","author":"Migueles","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2024.102372_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aar4526","article-title":"Identification and characterization of HIV-specific resident memory CD8+ T\u00a0cells in human lymphoid tissue","volume":"3","author":"Buggert","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01152","article-title":"Functional invariant natural killer t\u00a0cells secreting cytokines are associated with non-progressive human immunodeficiency virus-1 infection but not with suppressive anti-retroviral treatment","volume":"9","author":"Singh","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood-2001-12-0196","article-title":"Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among V\u03b124+V\u03b211+ NKT cell subsets with distinct cytokine-producing capacity","volume":"100","author":"Kim","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102372_bib17","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1365-2567.2003.01560.x","article-title":"CD1d-restricted natural killer T\u00a0cells are potent targets for human immunodeficiency virus infection","volume":"108","author":"Fleuridor","year":"2003","journal-title":"Immunology"},{"key":"10.1016\/j.omtn.2024.102372_bib18","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.168.3.1490","article-title":"Selective Decrease in Circulating V 24+V 11+ NKT Cells During HIV Type 1 Infection","volume":"168","author":"van der Vliet","year":"2002","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2104721118","article-title":"Preferential and persistent impact of acute HIV-1 infection on CD4\u00a0+ iNKT cells in colonic mucosa","volume":"118","author":"Paquin-Proulx","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102372_bib20","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.4049\/jimmunol.177.9.5775","article-title":"Cutting Edge: Rapid Recovery of NKT Cells upon Institution of Highly Active Antiretroviral Therapy for HIV-1 Infection","volume":"177","author":"van der Vliet","year":"2006","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/mi.2012.101","article-title":"Preferential depletion of gut\u00a0CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection","volume":"6","author":"Ibarrondo","year":"2013","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib22","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1002\/eji.200838780","article-title":"Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection","volume":"39","author":"Moll","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice","volume":"53","author":"Laczko","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.omtn.2024.102372_bib24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102372_bib25","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib26","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib27","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.omtn.2024.102372_bib28","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.omtn.2024.102372_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41541-021-00307-6","article-title":"Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates","volume":"6","author":"Saunders","year":"2021","journal-title":"npj Vaccines"},{"key":"10.1016\/j.omtn.2024.102372_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110514","article-title":"mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice","volume":"38","author":"Mu","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2024.102372_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6502","article-title":"Vaccination induces HIV broadly neutralizing antibody precursors in humans","volume":"378","author":"Leggat","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.omtn.2024.102372_bib32","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/nm1520","article-title":"CD8\u00a0+ T-cell responses to different HIV proteins have discordant associations with viral load","volume":"13","author":"Kiepiela","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib33","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.omtm.2018.10.010","article-title":"Efficient Induction of T Cells against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-Amplifying mRNA","volume":"12","author":"Moyo","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2024.102372_bib34","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/vaccines8030360","article-title":"Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical T-cell immunogenicity and breadth","volume":"8","author":"Moyo","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.omtn.2024.102372_bib35","doi-asserted-by":"crossref","first-page":"945706","DOI":"10.3389\/fimmu.2022.945706","article-title":"Comparative immunogenicity of an mRNA\/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques","volume":"13","author":"Valentin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib36","first-page":"1655","article-title":"Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and \u03b1-GalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells","volume":"13","author":"Verbeke","year":"2019","journal-title":"ACS Nano"},{"key":"10.1016\/j.omtn.2024.102372_bib37","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1084\/jem.20030324","article-title":"Activation of natural killer T\u00a0cells by \u03b1-galactosylceramide rapidly induces the full maturation of dendritic cells in\u00a0vivo and thereby acts as an adjuvant for combined CD4 and CD8 T\u00a0cell immunity to a coadministered protein","volume":"198","author":"Fujii","year":"2003","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib38","doi-asserted-by":"crossref","first-page":"13015","DOI":"10.1021\/acsomega.9b00489","article-title":"Codelivery of mRNA with \u03b1-galactosylceramide using a new lipopolyplex formulation induces a strong antitumor response upon intravenous administration","volume":"4","author":"Guevara","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.omtn.2024.102372_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jconrel.2024.04.052","article-title":"Alpha-galactosylceramide improves the potency of mRNA LNP vaccines against cancer and intracellular bacteria","volume":"370","author":"Meulewaeter","year":"2024","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.omtn.2024.102372_bib41","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib42","first-page":"1","article-title":"Identification and characterization of HIV-specific resident memory CD8+ T\u00a0cells in human lymphoid tissue","volume":"24","author":"Buggert","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib43","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2008-10-182709","article-title":"Mucosal immune responses to HIV-1 in elite controllers : a potential correlate of immune control","volume":"113","author":"Ferre","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102372_bib44","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41385-021-00389-4","article-title":"Human gut-associated lymphoid tissues (GALT); diversity, structure, and function","volume":"14","author":"M\u00f6rbe","year":"2021","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib45","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","article-title":"HIV controllers exhibit potent CD8 T\u00a0cell capacity to suppress HIV infection ex\u00a0vivo and peculiar cytotoxic T lymphocyte activation phenotype","volume":"104","author":"Saez-Cirion","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.omtn.2024.102372_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2012-06-436295","article-title":"High-dimensional immunomonitoring models of HIV-1\u00a0\u2013 specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control","volume":"121","author":"Ndhlovu","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtn.2024.102372_bib47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.omtm.2022.10.001","article-title":"A third dose of the unmodified COVID-19 mRNA vaccine CVnCoV enhances quality and quantity of immune responses","volume":"27","author":"Lenart","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtn.2024.102372_bib48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3389\/fimmu.2015.00379","article-title":"The role of invariant natural killer T\u00a0cells in dendritic cell licensing, cross-priming, and memory CD8+ T\u00a0cell generation","volume":"6","author":"Gottschalk","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/ni.1848","article-title":"Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs","volume":"11","author":"Semmling","year":"2010","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib50","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","article-title":"Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib51","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/eji.201343740","article-title":"Dendritic cell subsets in the intestinal lamina propria: Ontogeny and function","volume":"43","author":"Persson","year":"2013","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib52","doi-asserted-by":"crossref","first-page":"9927","DOI":"10.1073\/pnas.1019037108","article-title":"Neonatal Fc receptor for IgG (FcRn) regulates cross-presentation of IgG immune complexes by CD8-CD11b+ dendritic cells","volume":"108","author":"Baker","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtn.2024.102372_bib53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/icb.2011.71","article-title":"ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway","volume":"90","author":"Wilson","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"10.1016\/j.omtn.2024.102372_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.110209","article-title":"Stimulation of a subset of natural killer T\u00a0cells by CD103+ DC is required for GM-CSF and protection from pneumococcal infection","volume":"38","author":"Murray","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtn.2024.102372_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103479","article-title":"The mRNA-LNP platform\u2019s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory","volume":"24","author":"Ndeupen","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.omtn.2024.102372_bib56","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/QAD.0000000000001276","article-title":"Preclinical evaluation of an\u00a0mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)","volume":"31","author":"Guardo","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.omtn.2024.102372_bib57","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2012.202","article-title":"Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines","volume":"21","author":"Pollard","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102372_bib58","first-page":"3","article-title":"Identification of HIV-Derived, HLA Class I Restricted CTL Epitopes: Insights into TCR Repertoire, CTL Escape and Viral Fitness","volume":"chapter I-A","author":"Frahm","year":"2006","journal-title":"HIV Mol. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib59","doi-asserted-by":"crossref","first-page":"7283","DOI":"10.1016\/j.vaccine.2015.10.111","article-title":"Analysis of T\u00a0cell responses to chimpanzee adenovirus vectors encoding HIV gag-pol-nef antigen","volume":"33","author":"Herath","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.omtn.2024.102372_bib60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.omtn.2024.102372_bib61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/JVI.01876-19","article-title":"A Novel Immunogen Selectively Eliciting CD8\u2d19 T Cells but Not CD4+ T Cells Targeting Immunodeficiency Virus Antigens","volume":"94","author":"Ishii","year":"2020","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtn.2024.102372_bib62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2022.884862","article-title":"Oral mRNA Vaccines Against Infectious Diseases- A Bacterial Perspective","volume":"13","author":"Jawalagatti","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib63","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41590-023-01562-6","article-title":"mRNA vaccine against malaria tailored for liver-resident memory T\u00a0cells","volume":"24","author":"Ganley","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omtn.2024.102372_bib64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/sj.cgt.7700499","article-title":"Efficient genetic modification of murine dendritic cells by electroporation with mRNA","volume":"9","author":"Van Meirvenne","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.omtn.2024.102372_bib65","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1128\/JVI.02080-07","article-title":"Efficient in vitro expansion of human immunodeficiency virus (HIV)-specific T-cell responses by gag mRNA-electroporated dendritic cells from treated and untreated HIV type 1-infected individuals","volume":"82","author":"Van Gulck","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.omtn.2024.102372_bib66","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1038\/s41385-019-0207-8","article-title":"Cesarean section increases sensitivity to oxazolone-induced colitis in C57BL\/6 mice","volume":"12","author":"Zachariassen","year":"2019","journal-title":"Mucosal Immunol."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:13:40Z","timestamp":1764177220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124002592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2162253124002592"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102372","relation":{},"ISSN":["2162-2531"],"issn-type":[{"value":"2162-2531","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of mRNA-galsomes and LNPs in enhancing HIV-specific T\u00a0cell responses across various lymphoid organs","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102372"}}